Clinical Trials Directory

Trials / Terminated

TerminatedNCT00978874

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Abramson Cancer Center at Penn Medicine · Academic / Other
Sex
Female
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This trial is studying fluorine F 18 EF5 PET/CT imaging to see how well it works in finding hypoxia in tumor cells of patients with locally advanced or recurrent/metastatic cervical cancer.

Detailed description

OBJECTIVES: * To determine if the presence and heterogeneity of hypoxia can be detected by fluorine F 18 EF5 binding in tumors during PET/CT imaging in patients with newly diagnosed or recurrent carcinoma of the cervix. * To determine if fludeoxyglucose F 18 uptake correlates with fluorine F 18 EF5 uptake. * To assess the relationship between fluorine F 18 EF5 uptake and disease-free and overall survival. OUTLINE: Patients are stratified according to disease stage (locally advanced vs recurrent or metastatic disease). Patients receive fluorine F 18 EF5 IV followed by PET/CT imaging from the base of skull to upper thigh at baseline and during radiotherapy or chemotherapy (i.e., at 3-4 weeks after the initiation of radiotherapy or after the 4th, 5th, or 6th course of chemotherapy). Patients also undergo fludeoxyglucose F 18 PET/CT imaging within 7 to 10 days of the second fluorine F 18 EF5 scan. After completion of study treatment, patients are followed up at 30 days and then annually thereafter.

Conditions

Interventions

TypeNameDescription
RADIATIONfludeoxyglucose F 18
RADIATIONfluorine F 18 EF5

Timeline

Start date
2008-05-01
Primary completion
2013-09-04
Completion
2013-09-04
First posted
2009-09-17
Last updated
2021-06-25
Results posted
2021-06-25

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00978874. Inclusion in this directory is not an endorsement.